Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (ZEUS)

Gilead Sciences

Status: Completed

Conditions: Follicular Non-Hodgkin's Lymphoma Refractory

Treatments: Drug: Idelalisib

Study type: Observational

Funder types: Industry

Identifiers

NCT03568929

GS-EU-313-4172

EUPAS19618 (Other Identifier)

Details and patient eligibility

About

The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

Enrollment: 257 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Individuals who were or are being treated for refractory Follicular Lymphoma (FL) according to the product information for idelalisib and treatment guidelines in routine clinical practice.

Exclusion criteria

• Individuals included in clinical trials on idelalisib within the timeframe of this study.

Trial design

257 participants in 1 patient group

Idelalisib

Description:

Participants who have been or are currently being treated with 100 or 150 mg of idelalisib

Treatment:

Drug: Idelalisib